Intracranial myeloid sarcoma presentation in distant acute myeloid leukemia remission.

Autor: Lee D; Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA; Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. Electronic address: dennis.lee@my.rfums.org., Omofoye OA; Department of Neurological Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: oluwaseun.omofoye@cshs.org., Karnati T; Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA. Electronic address: tkarnati@ucdavis.edu., Graff JP; Department of Pathology, University of California Davis, Sacramento, CA, USA. Electronic address: jpgraff@ucdavis.edu., Shahlaie K; Department of Neurological Surgery, University of California Davis, Sacramento, CA, USA. Electronic address: krshahlaie@ucdavis.edu.
Jazyk: angličtina
Zdroj: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2021 Jul; Vol. 89, pp. 158-160. Date of Electronic Publication: 2021 May 12.
DOI: 10.1016/j.jocn.2021.05.001
Abstrakt: Intracranial myeloid sarcoma (IMS) is a rare central nervous system manifestation of hematopoietic neoplasms of myeloid origin. We report the first case of IMS treatment with an isocitrate dehydrogenase-2 (IDH-2) inhibitor, Enasidenib, following surgical resection, whole-brain radiation, and consolidation Etoposide/Cytarabine therapy. A 42-year-old female was diagnosed with IMS after a 10-year remission of her acute myeloid leukemia (AML). She underwent surgical debulking and had postoperative resolution of her visual symptoms. She received adjuvant radiation and medical management, and continues to show no evidence of recurrence or progression at 17 months postoperatively. This case is notable for an isolated IMS presentation in a patient with a very distant history of AML remission, and without evidence of concurrent bone marrow relapse. The goals of neurosurgical intervention should be symptomatic relief of mass effect and pathological diagnosis, due to the sensitivity of IMS to adjuvant radiation and medical management such as IDH-2 inhibitors.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: